Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Boehringer Ingelheim Pharmaceuticals |
---|---|
Information provided by: | Boehringer Ingelheim Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00281580 |
To demonstrate that Micardis and Norvasc when used together are more effective at lowering blood pressure.
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Telmisartan Drug: Amlodipine |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 4x4 Factorial Design Trial to Evaluate Telmisartan 20, 40 and 80 mg Tablets in Combination With Amlodipine 2.5, 5 and 10 mg Capsules After Eight Weeks of Treatment in Patients With Stage I or II Hypertension, With an ABPM Sub-Study |
Enrollment: | 1461 |
Study Start Date: | April 2006 |
Primary Completion Date: | March 2007 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Chair: | Boehringer Ingelheim | Boehringer Ingelheim Pharmaceuticals |
Responsible Party: | Boehringer Ingelheim ( Boehringer Ingelheim, Study Chair ) |
Study ID Numbers: | 1235.1 |
Study First Received: | January 24, 2006 |
Last Updated: | December 12, 2008 |
ClinicalTrials.gov Identifier: | NCT00281580 |
Health Authority: | United States: Food and Drug Administration |
Calcium, Dietary Vascular Diseases Telmisartan |
Angiotensin II Amlodipine Hypertension |
Vasodilator Agents Molecular Mechanisms of Pharmacological Action Calcium Channel Blockers Enzyme Inhibitors Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |
Protease Inhibitors Membrane Transport Modulators Angiotensin II Type 1 Receptor Blockers Therapeutic Uses Angiotensin-Converting Enzyme Inhibitors Cardiovascular Diseases |